Bioporto has been chasing a crucial US approval for years. At an investor meeting, management spoke of progress, but also of a continued need for funding. Now the question is whether the biotech company can reach its long-awaited turning point without another capital raise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Bioporto has been chasing a crucial US approval for years. At an investor meeting, management spoke of progress, but also of a continued need for funding. Now the question is whether the biotech company can reach its long-awaited turning point without another capital raise